Mistras Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Mistras Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2017 | $700.97M | Mar 27, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $724.02M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $729.64M | Mar 11, 2026 |
| FY2023 | Dec 31, 2023 | $182.07M | Mar 11, 2024 |
| FY2023 | Sep 30, 2023 | $179.35M | Mar 11, 2024 |
| FY2023 | Jun 30, 2023 | $176.03M | Mar 11, 2024 |
| FY2023 | Mar 31, 2023 | $168.02M | Mar 11, 2024 |
| FY2023 | Dec 31, 2022 | $168.22M | Mar 11, 2024 |
| FY2023 | Sep 30, 2022 | $178.46M | Mar 11, 2024 |
| FY2023 | Jun 30, 2022 | $179.03M | Mar 11, 2024 |
| FY2023 | Mar 31, 2022 | $161.66M | Mar 11, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $180.76M | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | $182.17M | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | $191.79M | Mar 18, 2019 |
| FY2018 | Mar 31, 2018 | $187.63M | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | $187.64M | Mar 18, 2019 |
| FY2018 | Sep 30, 2017 | $179.57M | Mar 18, 2019 |
| FY2018 | Jun 30, 2017 | $170.44M | Mar 18, 2019 |
| FY2018 | Mar 31, 2017 | $163.32M | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $170.16M | Mar 18, 2019 |
| FY2018 | Sep 30, 2016 | $168.81M | Mar 18, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $204.51M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $192.17M | Mar 11, 2026 |
| FY2023 | Dec 31, 2023 | $53.63M | Mar 11, 2024 |
| FY2023 | Sep 30, 2023 | $54.38M | Mar 11, 2024 |
| FY2023 | Jun 30, 2023 | $49.72M | Mar 11, 2024 |
| FY2023 | Mar 31, 2023 | $46.08M | Mar 11, 2024 |
| FY2023 | Dec 31, 2022 | $50.94M | Mar 11, 2024 |
| FY2023 | Sep 30, 2022 | $53.78M | Mar 11, 2024 |
| FY2023 | Jun 30, 2022 | $53.56M | Mar 11, 2024 |
| FY2023 | Mar 31, 2022 | $39.89M | Mar 11, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.84M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $18.96M | Mar 11, 2026 |
| FY2023 | Dec 31, 2023 | ($2.51M) | Mar 11, 2024 |
| FY2023 | Sep 30, 2023 | ($10.30M) | Mar 11, 2024 |
| FY2023 | Jun 30, 2023 | $337.0K | Mar 11, 2024 |
| FY2023 | Mar 31, 2023 | ($4.99M) | Mar 11, 2024 |
| FY2023 | Dec 31, 2022 | $2.84M | Mar 11, 2024 |
| FY2023 | Sep 30, 2022 | $4.37M | Mar 11, 2024 |
| FY2023 | Jun 30, 2022 | $4.64M | Mar 11, 2024 |
| FY2023 | Mar 31, 2022 | ($5.36M) | Mar 11, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.57M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $39.83M | Mar 11, 2026 |
| FY2023 | Dec 31, 2023 | $706.0K | Mar 11, 2024 |
| FY2023 | Sep 30, 2023 | ($4.68M) | Mar 11, 2024 |
| FY2023 | Jun 30, 2023 | $3.89M | Mar 11, 2024 |
| FY2023 | Mar 31, 2023 | ($1.83M) | Mar 11, 2024 |
| FY2023 | Dec 31, 2022 | $5.80M | Mar 11, 2024 |
| FY2023 | Sep 30, 2022 | $9.11M | Mar 11, 2024 |
| FY2023 | Jun 30, 2022 | $9.58M | Mar 11, 2024 |
| FY2023 | Mar 31, 2022 | ($4.70M) | Mar 11, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.12M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.72M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.99M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $2.52M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $2.89M | May 5, 2023 |
| FY2021 | Dec 31, 2019 | $3.05M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $3.31M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $2.27M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.58M | Mar 18, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $139.88M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $135.45M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $147.24M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $166.40M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $161.33M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $157.16M | May 5, 2023 |
| FY2021 | Dec 31, 2019 | $168.62M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $165.70M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $151.83M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $91.06M | Mar 18, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.98M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $50.13M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $26.75M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $26.41M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $42.26M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $67.80M | May 5, 2023 |
| FY2021 | Dec 31, 2019 | $59.11M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $41.66M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $55.80M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $30.26M | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.67M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $17.90M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $20.85M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $12.59M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $18.16M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $15.40M | May 5, 2023 |
| FY2021 | Dec 31, 2019 | $22.05M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $20.58M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $19.31M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $9.09M | Mar 18, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $578.78M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $523.04M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $534.78M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $534.90M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $562.20M | May 5, 2023 |
| FY2021 | Dec 31, 2020 | $583.31M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $719.88M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $694.04M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $554.44M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $469.43M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $343.14M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $324.14M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $344.27M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $336.16M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $361.28M | May 5, 2023 |
| FY2021 | Dec 31, 2020 | $386.09M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $433.86M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $422.96M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $283.65M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $198.68M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $235.10M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $198.57M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $190.19M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $198.45M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $200.68M | May 5, 2023 |
| FY2021 | Dec 31, 2020 | $197.02M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $285.82M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $270.90M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $270.62M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $270.58M | Mar 14, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.83M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $181.44M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $187.35M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $199.64M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $205.44M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $206.01M | May 5, 2023 |
| FY2021 | Dec 31, 2019 | $282.41M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $279.26M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $203.44M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $169.94M | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.85M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($9.98M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($28.94M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($11.49M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($17.99M) | May 5, 2023 |
| FY2021 | Dec 31, 2020 | ($21.85M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $77.61M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $71.55M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $64.72M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $91.80M | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.01M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $18.32M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $17.65M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $20.49M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $24.11M | May 5, 2023 |
| FY2021 | Dec 31, 2020 | $25.76M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $15.02M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $25.54M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $27.54M | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $19.15M | Mar 18, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $177.99M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $169.65M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $190.40M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $191.25M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $202.57M | May 5, 2023 |
| FY2021 | Dec 31, 2020 | $220.22M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $254.71M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $290.62M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $166.88M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $87.30M | Mar 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 11, 2026 |
| FY2022 | Dec 31, 2022 | 0 | May 5, 2023 |
| FY2022 | Dec 31, 2021 | 0 | May 5, 2023 |
| FY2022 | Dec 31, 2020 | (3) | May 5, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Mar 18, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 11, 2026 |
| FY2022 | Dec 31, 2022 | 0 | May 5, 2023 |
| FY2022 | Dec 31, 2021 | 0 | May 5, 2023 |
| FY2022 | Dec 31, 2020 | (3) | May 5, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Mar 18, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | May 31, 2016 | 28.94M | Aug 15, 2016 |
| FY2016 | May 31, 2015 | 28.70M | Aug 15, 2016 |
| FY2015 | May 31, 2014 | 28.46M | Aug 12, 2015 |
| FY2014 | May 31, 2013 | 28.21M | Aug 8, 2014 |
| FY2013 | May 31, 2012 | 28.03M | Aug 14, 2013 |
| FY2012 | May 31, 2011 | 27.67M | Aug 14, 2012 |